- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is testing a new medicine, ABX464, for people aged 18 and over with moderate to severe ulcerative colitis. It aims to see if the medicine helps improve symptoms and gut healing more than a dummy medicine (placebo), and if it's safe to use.
For: Moderately to severely active ulcerative colitisFrance · Spain · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is testing a new medicine, ABX464, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps improve the gut lining and reduces symptoms after 8 weeks, and if it's safe to use.
For: Moderately to severely active ulcerative colitisFrance · Spain · Italy - Active not recruitingPHASE3
ABTECT - Maintenance
This study looks at a new drug, ABX464, for people with ulcerative colitis. It's for those who haven't responded well to other treatments. The study checks if ABX464 can help keep symptoms under control over a long time and if it is safe to use.
For: Ulcerative ColitisUnited States · Argentina · Australia